Aligned Genetics, Inc. (KOSDAQ:238120)

Market Cap	60.94B +45.4%
Revenue (ttm)	16.02B +1.5%
Net Income	2.91B -29.5%
EPS	206.00 -28.2%
Shares Out	14.06M
PE Ratio	21.04
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,366
Average Volume	43,511
Open	4,275.00
Previous Close	4,275.00
Day's Range	4,255.00 - 4,405.00
52-Week Range	3,015.00 - 6,050.00
Beta	0.47
RSI	51.24
Earnings Date	May 15, 2026

About Aligned Genetics

Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genetics, Inc. was founded in 2008 and is headquartered in Anyang-Si, South Korea.

• Industry: Laboratory Analytical Instruments
• Founded: 2008
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 238120

Financial Performance

In 2025, Aligned Genetics's revenue was 16.02 billion, an increase of 1.51% compared to the previous year's 15.78 billion. Earnings were 2.91 billion, a decrease of -29.47%.